JP7104625B2 - 骨関節炎を処置するためのｃ型ナトリウム利尿ペプチド変異体の使用 - Google Patents

骨関節炎を処置するためのｃ型ナトリウム利尿ペプチド変異体の使用 Download PDF

Info

Publication number
JP7104625B2
JP7104625B2 JP2018530079A JP2018530079A JP7104625B2 JP 7104625 B2 JP7104625 B2 JP 7104625B2 JP 2018530079 A JP2018530079 A JP 2018530079A JP 2018530079 A JP2018530079 A JP 2018530079A JP 7104625 B2 JP7104625 B2 JP 7104625B2
Authority
JP
Japan
Prior art keywords
cnp
cartilage
gly
osteoarthritis
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018530079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505486A (ja
JP2019505486A5 (enExample
Inventor
チャールズ エイ． オニール
トッド エム． オッペニール
ジェイソン ケイ． ピンクスタッフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Publication of JP2019505486A publication Critical patent/JP2019505486A/ja
Publication of JP2019505486A5 publication Critical patent/JP2019505486A5/ja
Application granted granted Critical
Publication of JP7104625B2 publication Critical patent/JP7104625B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018530079A 2015-12-08 2016-12-08 骨関節炎を処置するためのｃ型ナトリウム利尿ペプチド変異体の使用 Active JP7104625B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562264682P 2015-12-08 2015-12-08
US62/264,682 2015-12-08
PCT/US2016/065520 WO2017100400A2 (en) 2015-12-08 2016-12-08 Use of c-type natriuretic peptide variants to treat osteoarthritis

Publications (3)

Publication Number Publication Date
JP2019505486A JP2019505486A (ja) 2019-02-28
JP2019505486A5 JP2019505486A5 (enExample) 2020-01-23
JP7104625B2 true JP7104625B2 (ja) 2022-07-21

Family

ID=59013378

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018530079A Active JP7104625B2 (ja) 2015-12-08 2016-12-08 骨関節炎を処置するためのｃ型ナトリウム利尿ペプチド変異体の使用

Country Status (17)

Country Link
US (2) US11202819B2 (enExample)
EP (2) EP4019038A3 (enExample)
JP (1) JP7104625B2 (enExample)
KR (1) KR102941538B1 (enExample)
CN (1) CN108697766A (enExample)
AU (2) AU2016365751B2 (enExample)
CA (1) CA3007315A1 (enExample)
DK (1) DK3386531T3 (enExample)
ES (1) ES2901769T3 (enExample)
HR (1) HRP20211908T1 (enExample)
HU (1) HUE057083T2 (enExample)
IL (1) IL259690B2 (enExample)
MX (1) MX2018006986A (enExample)
PL (1) PL3386531T3 (enExample)
PT (1) PT3386531T (enExample)
RU (1) RU2759679C2 (enExample)
WO (1) WO2017100400A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017205693B2 (en) 2016-01-08 2022-03-31 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
JP6968802B2 (ja) 2016-01-08 2021-11-17 アセンディス ファーマ グロース ディスオーダーズ エー／エス 環部分にキャリア結合を有するｃｎｐプロドラッグ
CA3008015A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
EP4710947A3 (en) 2016-01-08 2026-06-17 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
KR102518217B1 (ko) 2016-01-08 2023-04-04 아센디스 파마 그로우쓰 디스오더스 에이/에스 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제
US10835578B2 (en) 2016-01-08 2020-11-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
RU2768747C2 (ru) 2016-09-29 2022-03-24 Асцендис Фарма Гроус Дизордерс А/С Комбинаторная терапия с агонистами cnp контролируемого высвобождения
CN112752556A (zh) * 2018-04-27 2021-05-04 雷米生物科学公司 新的医疗装置、递送运载体及其制造
EP3923906A1 (en) * 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
CN116635027A (zh) * 2020-11-25 2023-08-22 普罗林科斯有限责任公司 C-利钠肽的延长释放水凝胶偶联物
WO2022240936A1 (en) * 2021-05-11 2022-11-17 Texas Tech University System Targeted selenium conjugates as countermeasures for pathogenic viruses and cells
CA3242257A1 (en) * 2021-12-07 2023-06-15 Biomarin Pharmaceutical Inc. C-type natriuretic peptide therapy of bone-related disorders
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
KR102866559B1 (ko) 2022-11-02 2025-10-02 노보 노르디스크 에이/에스 Cnp 화합물
KR20250162619A (ko) 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
KR20250098109A (ko) * 2023-12-21 2025-07-01 주식회사 펩트론 나트륨이뇨 펩타이드 유사체 및 이의 용도
CN117801123B (zh) * 2024-02-29 2024-05-03 天津凯莱英生物科技有限公司 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094889A1 (ja) 2004-03-31 2005-10-13 Chugai Seiyaku Kabushiki Kaisha 関節炎症治療剤又は予防剤
JP2012527244A (ja) 2009-05-20 2012-11-08 バイオマリン ファーマシューティカル インコーポレイテッド Ｃ型ナトリウム利尿ペプチドの変異体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
KR20070007842A (ko) * 2004-03-31 2007-01-16 카즈와 나카오 신장증가용 조성물
AR069409A1 (es) 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
JP6055779B2 (ja) * 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094889A1 (ja) 2004-03-31 2005-10-13 Chugai Seiyaku Kabushiki Kaisha 関節炎症治療剤又は予防剤
JP2012527244A (ja) 2009-05-20 2012-11-08 バイオマリン ファーマシューティカル インコーポレイテッド Ｃ型ナトリウム利尿ペプチドの変異体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biochem.Biophys.Res.Commun.，2015年08月，Vol.465，pp.784-789
Macromolecules，2015年01月，Vol.16，pp.524-531

Also Published As

Publication number Publication date
AU2016365751A1 (en) 2018-06-21
RU2021132347A (ru) 2022-03-24
EP4019038A2 (en) 2022-06-29
CA3007315A1 (en) 2017-06-15
PL3386531T3 (pl) 2022-02-28
AU2016365751B2 (en) 2023-12-21
RU2759679C2 (ru) 2021-11-16
PT3386531T (pt) 2021-12-29
KR20180088459A (ko) 2018-08-03
US11202819B2 (en) 2021-12-21
IL259690B (en) 2022-10-01
US12214015B2 (en) 2025-02-04
EP3386531B1 (en) 2021-10-13
RU2018124600A3 (enExample) 2020-01-13
ES2901769T3 (es) 2022-03-23
RU2018124600A (ru) 2020-01-13
AU2024201852A1 (en) 2024-04-11
WO2017100400A3 (en) 2017-10-26
EP3386531A2 (en) 2018-10-17
US20190247467A1 (en) 2019-08-15
EP4019038A3 (en) 2022-09-28
CN108697766A (zh) 2018-10-23
MX2018006986A (es) 2018-09-05
WO2017100400A2 (en) 2017-06-15
HRP20211908T1 (hr) 2022-03-04
JP2019505486A (ja) 2019-02-28
KR102941538B1 (ko) 2026-03-19
IL259690A (en) 2018-07-31
DK3386531T3 (da) 2022-01-03
HUE057083T2 (hu) 2022-04-28
US20220160836A1 (en) 2022-05-26
IL259690B2 (en) 2023-02-01

Similar Documents

Publication Publication Date Title
US12214015B2 (en) Use of c-type natriuretic peptide variants to treat osteoarthritis
TWI471137B (zh) Ｃ型利鈉胜肽變異體
US8377884B2 (en) Variants of C-type natriuretic peptides
JP6882256B2 (ja) 骨格異形成症を処置するためのｃ型ナトリウム利尿ペプチド変異体の使用
US20220331398A1 (en) Methods and compositions for treatment of cartilage damage and arthritis
RU2850341C2 (ru) Применение вариантов натрийуретического пептида типа c для лечения остеоартрита
HK40074902A (en) Use of c-type natriuretic peptide variants to treat osteoarthritis
HK1262398B (en) Use of c-type natriuretic peptide variants to treat osteoarthritis
RU2777504C2 (ru) Способы и композиции для лечения повреждения хряща и артрита
HK40124042A (en) Variants of c-type natriuretic peptide
HK40130436A (en) Variants of c-type natriuretic peptide
HK1239519B (en) Variants of c-type natriuretic peptide
HK1168279B (en) Variants of c-type natriuretic peptide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201202

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220328

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220708

R150 Certificate of patent or registration of utility model

Ref document number: 7104625

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250